The Cambridge team's Cell Reports study (in vitro stem-cell-derived organoids, no human subjects, batch sizes typical of such models at n<10 per condition) demonstrates that axon regrowth capacity in cortico-spinal projections declines sharply after ~150 days in culture, corresponding to mid-gestation, via a gene-regulatory network that can be pharmacologically reopened with lynestrenol. This work extends the group's 2021 organoid models of motor neuron disease by adding functional spinal cord and muscle components, creating the first human multi-region circuit in a dish. Unlike many incremental rodent crush-injury papers that emphasize glial scarring, this study isolates neuron-autonomous mechanisms and identifies a repurposed contraceptive as a hit from in silico screening. Limitations are clear: organoids lack vascular, immune, and biomechanical cues of the adult CNS, so translation risk remains high; no randomized data or even ex vivo human tissue validation yet exists. Related work in Nature Neuroscience (2024) on human iPSC-derived neurons similarly found maturation-dependent loss of regenerative transcription factors, while a 2022 Lancet Neurology review on MS and traumatic injury notes that neuron-intrinsic targets have been under-pursued relative to immunomodulatory trials. The finding reframes "irreversible" damage as potentially timed and reversible if interventions occur before full synaptic maturation, with implications for both congenital and adult-onset conditions.